MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) will present late-breaking Phase 1 data on DA-1726, a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for obesity, in a poster at EASL Congress 2026 in Barcelona, May 27–30, 2026.
The 16-week Phase 1 Part 3 titration study evaluates higher doses, safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory noninvasive liver assessments, with data expected in Q4 2026.
Positive
- None.
Negative
- None.
News Market Reaction – MTVA
On the day this news was published, MTVA declined 4.59%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $271K from the company's valuation, bringing the market cap to $5.63M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 10 | Phase 1 dosing update | Positive | +18.5% | First patient dosed in higher-dose Part 3 Phase 1 DA-1726 obesity study. |
| Mar 26 | Earnings and update | Positive | +1.5% | Year-end 2025 results with positive DA-1726 and vanoglipel data and funding runway. |
| Mar 18 | Trial approval | Positive | -2.6% | IRB approval for higher-dose DA-1726 Phase 1 cohorts in obese adults. |
| Mar 12 | Patent expansion | Positive | -1.2% | Expanded global patent portfolio for vanoglipel supporting protection through 2035. |
| Mar 04 | Investor forum | Neutral | +3.2% | Announcement of CEO presentation at virtual investor forum on obesity therapies. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed reactions: some positive clinical and corporate updates led to gains, while other favorable clinical and IP milestones saw modest declines.
Over the last few months, MetaVia has focused on advancing DA-1726 and vanoglipel. On Mar 18, it received IRB approval for higher-dose Phase 1 studies of DA-1726, followed by year-end 2025 results on Mar 26 highlighting clinical progress and cash of $10.3M. Dosing of the first patient in the higher-dose DA-1726 Phase 1 Part 3 study was announced on Apr 10. Alongside, MetaVia expanded vanoglipel patent protection into 2035 and engaged investors via a virtual forum, underscoring continued development of its cardiometabolic pipeline.
Key Terms
glp-1 medical
glucagon medical
oxyntomodulin medical
pharmacokinetics medical
pharmacodynamics medical
phase 1 medical
titration medical
poster presentation technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
"Having a late-breaking abstract on DA-1726 accepted for a poster presentation at the prestigious EASL Congress underscores the strength of this asset," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "DA-1726 continues to demonstrate potential for a differentiated, best-in-class profile and is currently being evaluated in a 16-week Phase 1 Part 3 titration study designed to optimize higher dose levels and tolerability, with data expected in the fourth quarter of this year."
- Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment
- Presenting Author: Chris Fang, Chief Medical Officer, MetaVia
- Abstract Number: LB26-5204
- Final Abstract ID:
LBP-010 - Session: Late Breaking Posters
- Presentation Date: Wednesday, May 27, 2026
- Presentation Start: 8:30 am CET
A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.
About DA-1726
DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-data-highlighting-da-1726-a-glp-1glucagon-dual-agonist-in-a-late-breaking-poster-presentation-at-the-easl-congress-2026-302767663.html
SOURCE MetaVia Inc.